Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction.
Translate Bio Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$37.36|
|52 Week High||US$11.91|
|52 Week Low||US$37.99|
|1 Month Change||-0.80%|
|3 Month Change||99.15%|
|1 Year Change||161.44%|
|3 Year Change||261.32%|
|5 Year Change||n/a|
|Change since IPO||224.31%|
Recent News & Updates
|TBIO||US Biotechs||US Market|
Return vs Industry: TBIO exceeded the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: TBIO exceeded the US Market which returned 30.7% over the past year.
Stable Share Price: TBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: TBIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2.
Translate Bio Fundamentals Summary
|TBIO fundamental statistics|
Is TBIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TBIO income statement (TTM)|
|Cost of Revenue||US$73.98m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.54|
|Net Profit Margin||17.97%|
How did TBIO perform over the long term?See historical performance and comparison
Is Translate Bio undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TBIO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TBIO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TBIO is poor value based on its PE Ratio (69.8x) compared to the US Biotechs industry average (24.4x).
PE vs Market: TBIO is poor value based on its PE Ratio (69.8x) compared to the US market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: TBIO's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: Insufficient data to calculate TBIO's PB Ratio to determine if it is good value.
How is Translate Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TBIO's earnings are forecast to decline over the next 3 years (-45.2% per year).
Earnings vs Market: TBIO's earnings are forecast to decline over the next 3 years (-45.2% per year).
High Growth Earnings: TBIO's earnings are forecast to decline over the next 3 years.
Revenue vs Market: TBIO's revenue is expected to decline over the next 3 years (-5% per year).
High Growth Revenue: TBIO's revenue is forecast to decline over the next 3 years (-5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TBIO's Return on Equity is forecast to be low in 3 years time (1%).
How has Translate Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TBIO has high quality earnings.
Growing Profit Margin: TBIO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: TBIO has become profitable over the past 5 years, growing earnings by 10.3% per year.
Accelerating Growth: TBIO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: TBIO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: TBIO's Return on Equity (9.8%) is considered low.
How is Translate Bio's financial position?
Financial Position Analysis
Short Term Liabilities: TBIO's short term assets ($717.0M) exceed its short term liabilities ($81.5M).
Long Term Liabilities: TBIO's short term assets ($717.0M) exceed its long term liabilities ($410.7M).
Debt to Equity History and Analysis
Debt Level: TBIO is debt free.
Reducing Debt: TBIO has not had any debt for past 5 years.
Debt Coverage: TBIO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TBIO has no debt, therefore coverage of interest payments is not a concern.
What is Translate Bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Renaud (52 yo)
Mr. Ronald C. Renaud, Jr., also known as Ron, MBA, has been the Chief Executive Officer of Translate Bio, Inc. since November 2014 and served as its Interim Principal Financial Officer since December 27, 2...
CEO Compensation Analysis
Compensation vs Market: Ron's total compensation ($USD3.34M) is below average for companies of similar size in the US market ($USD5.19M).
Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.
Experienced Management: TBIO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: TBIO's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TBIO insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Translate Bio, Inc.'s employee growth, exchange listings and data sources
- Name: Translate Bio, Inc.
- Ticker: TBIO
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.824b
- Shares outstanding: 75.59m
- Website: https://www.translate.bio
Number of Employees
- Translate Bio, Inc.
- 29 Hartwell Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/15 08:32|
|End of Day Share Price||2021/09/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.